Suggested remit: To appraise the clinical and cost effectiveness of palopegteriparatide within its marketing authorisation for treating hypoparathyroidism.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- Scoping commencing
- Process:
- STA Standard
- ID number:
- 6380
Provisional Schedule
- Committee meeting:
- 07 October 2025
- Expected publication:
- 17 December 2025
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Stakeholders
- Companies sponsors
- Ascendis Pharma (palopegteriparatide)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Amend
- Butterfly Thyroid Cancer Trust
- British Thyroid Foundation
- Kidney Care UK
- National Kidney Federation
- Parathyroid UK
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Thyroid UK
- Professional groups
- Association of Anaesthetists
- Association of Surgeons of Great Britain and Ireland
- British Association of Endocrine and Thyroid Surgeons
- British Association of Surgical Oncology
- British Geriatrics Society
- British Society for Haematology
- British Thyroid Association
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Endocrinology
- UK Clinical Pharmacy Association
- UK Kidney Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- AAH Pharmaceuticals (alfacalcidol, calcitriol, calcium carbonate, calcium gluconate, teriparatide)
- Accord Healthcare UK (calcium carbonate, calcium gluconate)
- Alliance Healthcare (alfacalcidol, calcitriol)
- Atnahs Pharma UK (calcitriol, chlortalidone, hydrochlorothiazide)
- Aurobindo Pharma (hydrochlorothiazide)
- B.Braun Medical (calcium gluconate)
- Boehringer Ingelheim (hydrochlorothiazide)
- Brown & Burk UK (hydrochlorothiazide)
- Crescent Pharma (alfacalcidol)
- Daiichi Sankyo UK (hydrochlorothiazide)
- Eli Lilly (teriparatide)
- Essential Healthcare (alfacalcidol, calcium carbonate)
- Forum Health Products (calcium carbonate)
- Galderma UK (calcitriol)
- Galen (calcium carbonate)
- Gedeon Richter UK (teriparatide)
- Glenmark Pharmaceuticals (hydrochlorothiazide)
- Grunenthal (calcium carbonate)
- Haleon UK (calcium carbonate)
- HealthAid (calcium carbonate)
- Hameln Pharma (calcium gluconate)
- Internis Pharmaceuticals (calcium carbonate)
- Mylan (calcium carbonate, hydrochlorothiazide)
- Kyowa Kirin (calcium carbonate)
- Medihealth Northern (alfacalcidol, calcitriol, chlortalidone)
- Mylan (bendroflumethiazide, indapamide)
- Morningside Healthcare (chlortalidone)
- Neon Healthcare (alfacalcidol, calcium carbonate)
- Novartis Pharmaceuticals (hydrochlorothiazide)
- Organon Pharma UK (hydrochlorothiazide)
- Pfizer (hydrochlorothiazide)
- Phoenix Healthcare Distribution (alfacalcidol, calcitriol, calcium carbonate)
- Ranbaxy UK (teriparatide)
- Roche Products (calcitriol)
- Sandoz (calcium carbonate)
- Sanofi (hydrochlorothiazide)
- Sigma Pharmaceuticals (alfacalcidol, bendroflumethiazide, calcitriol, chlortalidone, hydrochlorothiazide, indapamide)
- Stirling Anglian Pharmaceuticals (calcium carbonate)
- Strides Pharma (alfacalcidol)
- Takeda UK (calcium carbonate, recombinant human parathyroid hormone)
- Teva UK (calcitriol, teriparatide)
- Theramex (alfacalcidol)
- Thornton and Ross (teriparatide, hydrochlorothiazide)
- TriOn Pharma (alfacalcidol, calcium carbonate)
- Wockhardt UK (chlortalidone, hydrochlorothiazide)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Cochrane Metabolic & Endocrine Disorders Group
- Cochrane Haematology
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 February 2025 | The company has asked NICE to pause this appraisal to allow them more time to finalise their submission. |
| 24 September 2024 | Invitation to participate |
| 31 May 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late September 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 15 March 2024 - 16 April 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6380 |
| 15 March 2024 | In progress |
| 09 November 2023 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual